\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ shunt\\ placement\\ followed\\ by\\ radiation\\ therapy\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ mass\\ involving\\ the\\ midbrain\\ tectal\\ plate\\ and\\ posterior\\ third\\ ventricle\\.\ \(0\)\
\-\ \\â\\€\\¢\\ secondary\\ obstructive\\ hydrocephalus\\ both\\ lateral\\ ventricles\ \(0\)\
\-\ third\\ ventricle\\ anaplastic\\ astrocytoma\\,\\ grade\\ iii\\,\\ grade\\ 3\ \(0\)\
\-\ \\â\\€\\¢\\ glioma\\ \\(astrocytoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ pineal\\ region\\ tumor\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 56\\ year\\ old\\ man\\ with\\ a\\ two\\ week\\ history\\ of\\ headaches\\ and\\ visual\\ problems\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ third\\:\\ 0\\.27451571037951195\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.2721697623565251\ \(0\)\
\-\ ventricle\\:\\ 0\\.26538284863686096\ \(0\)\
\-\ grade\\:\\ 0\\.2592545768465329\ \(0\)\
\-\ tectal\\:\\ 0\\.24075424077701787\ \(0\)\
\-\ midbrain\\:\\ 0\\.20066737378333252\ \(0\)\
\-\ pineal\\:\\ 0\\.19875154449390153\ \(0\)\
\-\ anaplastic\\:\\ 0\\.19783549470247536\ \(0\)\
\-\ shunt\\:\\ 0\\.17093088391869563\ \(0\)\
\-\ 56\\:\\ 0\\.16834217956347378\ \(0\)\
\-\ obstructive\\:\\ 0\\.16763989499526494\ \(0\)\
\-\ plate\\:\\ 0\\.16529797154273884\ \(0\)\
\-\ ventricles\\:\\ 0\\.1583755491796285\ \(0\)\
\-\ problems\\:\\ 0\\.15636842997115277\ \(0\)\
\-\ iii\\:\\ 0\\.1556474518176608\ \(0\)\
\-\ visual\\:\\ 0\\.15380158382534437\ \(0\)\
\-\ glioma\\:\\ 0\\.15313626440932043\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.147155932411609\ \(0\)\
\-\ placement\\:\\ 0\\.14076494306396692\ \(0\)\
\-\ headaches\\:\\ 0\\.1344639358792284\ \(0\)\
\-\ involving\\:\\ 0\\.12626646442133246\ \(0\)\
\-\ followed\\:\\ 0\\.12173176180007948\ \(0\)\
\-\ week\\:\\ 0\\.12124805585138902\ \(0\)\
\-\ radiation\\:\\ 0\\.11945954757802499\ \(0\)\
\-\ enhancing\\:\\ 0\\.11292619451104803\ \(0\)\
\-\ region\\:\\ 0\\.10782726221160212\ \(0\)\
\-\ lymphoma\\:\\ 0\\.10735985263070319\ \(0\)\
\-\ two\\:\\ 0\\.10705204333025131\ \(0\)\
\-\ secondary\\:\\ 0\\.10684849025932822\ \(0\)\
\-\ therapy\\:\\ 0\\.10357478591407072\ \(0\)\
\-\ both\\:\\ 0\\.10052544501396952\ \(0\)\
\-\ metastatic\\:\\ 0\\.09886714813858663\ \(0\)\
\-\ man\\:\\ 0\\.09543531421299198\ \(0\)\
\-\ tumor\\:\\ 0\\.09428982948368393\ \(0\)\
\-\ posterior\\:\\ 0\\.09321735311331032\ \(0\)\
\-\ lateral\\:\\ 0\\.08946229653194314\ \(0\)\
\-\ by\\:\\ 0\\.07655160359041026\ \(0\)\
\-\ disease\\:\\ 0\\.07566946547012132\ \(0\)\
\-\ and\\:\\ 0\\.0744997233591116\ \(0\)\
\-\ history\\:\\ 0\\.06887223219346086\ \(0\)\
\-\ mass\\:\\ 0\\.06885698418110249\ \(0\)\
\-\ year\\:\\ 0\\.05555458086023459\ \(0\)\
\-\ old\\:\\ 0\\.05335162832122998\ \(0\)\
\-\ the\\:\\ 0\\.035969695218265804\ \(0\)\
\-\ with\\:\\ 0\\.03529843099963264\ \(0\)\
\-\ of\\:\\ 0\\.03527735278974689\ \(0\)\
